Once‐Daily Inhaled Budesonide for the Treatment of Asthma: Clinical Evidence and Pharmacokinetic Explanation

Background. Budesonide, a widely used inhaled corticosteroid (ICS) with a favorable therapeutic ratio, is available via a dry powder inhaler (Pulmicort Turbuhaler®) and as a suspension for nebulization (Pulmicort Respules®). Methods. MEDLINE and an AstraZeneca database were searched to identify relevant controlled clinical trials published between 1986 and 2002 using the key words budesonide OR inhaled corticosteroid, AND once daily. Results. Thirty‐four controlled clinical studies involving once‐daily administration of budesonide to asthmatic patients were identified. Excluding long‐term studies, this review presents data from 23 controlled studies for 4466 adults or adolescents and 1532 children with asthma and demonstrates efficacy of budesonide in both corticosteroid‐naïve patients and patients previously treated with ICS. Once‐daily administration of budesonide achieves clinical efficacy comparable with that of twice‐daily regimens in patients with mild‐to‐moderate asthma and is equally effective when given in the morning or evening. Once‐daily administration simplifies treatment regimens and may improve patient compliance. The tolerability profiles of budesonide once‐daily via Turbuhaler® or as budesonide inhalation suspension are good and comparable with those for twice‐daily dosing. Conclusions. Once‐daily budesonide is effective and well tolerated as initial treatment for adults and children with mild asthma and as maintenance therapy in patients with more severe asthma once asthma control has been achieved.